Alexion Pharmaceuticals, Inc.
News and overview for Alexion Pharmaceuticals, Inc.
Data on Alexion Pharmaceuticals' Soliris to be presented at the ASH meeting
News-Medical.Net | 13 days 17 hours ago
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that researchers are scheduled to present data relating to Soliris® (eculizumab) as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) during the 51st Annual Meeting of the American Society of Hematology (ASH), to be held December 5 â?? 8, 2009 at the Ernst N
Alexion 3Q profit surges, guidance increased
Forbes | 33 days 7 hours 47 minutes ago
CHESHIRE, Conn. -- Alexion Pharmaceuticals Inc. said Thursday its third-quarter profit surged 36 percent on sales of its blood disorder treatment Soliris, its only marketed product.
Alexion to Present at Credit Suisse s 2009 Healthcare Conference [Press Release]
Business Wire | 19 days 3 hours 21 minutes ago
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Dr. Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will present at Credit Suisse’s 2009 Healthcare Conference in Phoenix, Arizona at 8:00 a.m., local time (10:00 a.m. ET) on Thursday, November 12, 2009.
Alexion to Present at the Oppenheimer 20th Annual Healthcare Conference [Press Release]
Business Wire | 27 days 8 hours 33 minutes ago
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Dr. Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will present at the Oppenheimer 20th Annual Healthcare Conference in New York City at 3:55 p.m. ET on Wednesday, November 4, 2009.
Alexion Pharmaceuticals to Report Third Quarter 2009 Results on October 22, 2009 [Press Release]
Business Wire | 43 days 9 hours 8 minutes ago
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), today announced that the Company will report its financial results for the third quarter ended September 30, 2009 on Thursday, October 22, 2009 before the financial markets open. Following the release of the financial results, Alexion management will conduct a conference call and audio web cast on Thursday, October 22, 2009, at 10:00 a.m. Eastern Time (ET).
UPDATE 2-Alexion Q3 results beat Street, raises FY view
Reuters | 33 days 9 hours 25 minutes ago
BANGALORE, Oct 22 (Reuters) - Alexion Pharmaceuticals Inc (ALXN.O) posted better-than-expected quarterly results, helped by the addition of new patients receiving its genetic disorder drug Soliris in the United States and Europe, and raised its full-year outlook.
CORRECTED - CORRECTED-UPDATE 1-Alexion Q3 results beat Street, raises FY vie
Reuters | 33 days 10 hours 40 minutes ago
Oct 22 (Reuters) - Alexion Pharmaceuticals Inc (ALXN.O) posted better-than-expected quarterly results, helped by the addition of new patients receiving its genetic disorder drug Soliris in the United States and Europe, and raised its fiscal year outlook.
Prix Galien USA Announces 2009 Final Candidates [Press Release]
PRNewswire | 109 days 14 hours 7 minutes ago
...the Prix Galien USA committee recognized Selzentry(TM)( )(Pfizer Inc.), Isentress(R) (Merck & Co., Inc.), Soliris(R) (Alexion Pharmaceuticals, Inc.), INFUSE(R) (Wyeth) and Revlimid(R)( )(The Celgene Corporation...
BEFORE THE BELL-Alexion shares rise after results, outlook
Forbes | 33 days 8 hours 45 minutes ago
NEW YORK, Oct 22 (Reuters) - Shares of Alexion Pharmaceuticals Inc rose 6.5 percent to $47 in premarket trading on Thursday, after the company reported its third-quarter results and raised its full-year outlook.
Alexion Pharmaceuticals Inc. Leads Tech Top 40 Listings
Hartford Courant (Conn.), The | 24 days 14 hours 34 minutes ago
The state's economy might have slowed to a crawl, but one Connecticut company boasted revenue growth of 17,371 percent in the past four years.
US HOT STOCKS: EBay, New York Times, PNC Financial
Wall Street Journal, The | 29 days 6 hours 42 minutes ago
US stocks were mixed Thursday as the Dow Jones Industrial rose 45 points to 9995, the S&P 500 rose 0.14 points to 1082 and the Nasdaq Composite slipped 10 points to 2140. Among the companies whose shares are actively trading in Thursday's session are eBay Inc. (EBAY), New York Times Co. (NYT) and PNC Financial Services Group Inc. (PNC).
US HOT STOCKS: EBay, New York Times, PNC Fincl, Janus
Wall Street Journal, The | 29 days 5 hours 57 minutes ago
US stocks gained Thursday as the Dow Jones Industrial rose 93 points to 10042, the S&P 500 increased 5 points to 1086 and the Nasdaq Composite climbed 2 points to 2153. Among the companies whose shares are actively trading in Thursday's session are eBay Inc. (EBAY), New York Times Co. (NYT) and PNC Financial Services Group Inc. (PNC).
US HOT STOCKS: Amazon.com, Broadcom Acitve In Late Trading
Wall Street Journal, The | 29 days 5 hours 51 minutes ago
US stocks gained Thursday as the Dow Jones Industrial rose 132 points to 10081, the S&P 500 increased 11 points to 1092 and the Nasdaq Composite climbed 14 points to 2165
Blazing New Trials: Participants In Drug Tests Balance Risks With Hopes For Breakthrough
Hartford Courant (Conn.), The | 23 days 20 hours 24 minutes ago
After years working as a flight attendant, Jayne Valente was looking forward to launching her own interior-decorating business. But then came the stomachaches, a side effect of the medication she had taken to treat osteoporosis , a disease that can cause brittle and broken bones.
Employer groups work to protect flexible spending accounts in health care bills
Hartford Courant (Conn.), The | 23 days 9 hours 47 minutes ago
WASHINGTON (AP) — Those tax-free spending accounts that you and your co-workers use to help pay for dental work, insurance copayments or over-the-counter drugs face a hit under the health overhaul bills in Congress — unless a coalition that includes a powerful union, insurers and others can stop it.
Sign up for BIO SmartBrief
Company Overview
| Company: | Alexion Pharmaceuticals, Inc. |
|---|---|
| Industry: | Biopharmaceuticals & Biotherapeutics |
| Website: | http://www.alexionpharm.com |
Alexion Pharmaceuticals can't suppress its enthusiasm for treating immune functions gone awry. The firm develops drugs that inhibit certain immune system functions that cause autoimmune disorders, cancers, and other diseases. The company's first marketed antibody product, Soliris, has won approval in the US, Canada, and the European Union for the treatment of a rare genetic blood disorder known as paroxysmal nocturnal hemoglobinuria (PNH). Alexion is developing the same antibody (eculizumab) used in Soliris as a potential treatment for other autoimmune and inflammatory conditions. The company has additional development programs for cancer-fighting antibodies.
Key Numbers
| Sales in U.S. Dollars (mil.) | 259.1 (2008) |
|---|---|
| One-year % Growth in Sales | 259.7 (2008) |
| Net Income in U.S. Dollars (mil.) | 33.1 (2008) |
| One-year % Growth in Net Income | 0.0 (2008) |
| Number of Employees | 504 (2008) |
| One-year % Growth in Number of Employees | 16.1 (2008) |
| Fiscal Year-End | December |